GRI Bio, Inc. (GRI) shareholders
Close on Nov 17, 2026Market cap $2.95MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Mitchell P. Kopin Joint filing with Daniel B. Asher (9.99%), Intracoastal Capital LLC (9.99%) | 1,097,858 | 9.99% | 13G (passive) amendment | Dec 31, 2025 |
| Intracoastal Capital, LLC Joint filing with Mitchell P. Kopin (9.99%), Daniel B. Asher (9.99%) | 677,477 | 9.99% | 13G (passive) | Dec 11, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of GRI | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Hrt Financial LP | 28,784 | 1.32% | $50.00K | New | 0.00% |
| Vanguard Capital Management LLC | 21,368 | 0.98% | $37.82K | New | 0.00% |
| Geode Capital Management, LLC | 13,869 | 0.63% | $24.55K | −4,569 | 0.00% |
| Citadel Advisors LLC | 13,376 | 0.61% | $23.68K | New | 0.00% |
| Morgan Stanley | 8,737 | 0.40% | $15.46K | New | 0.00% |
| UBS Group AG | 4,920 | 0.23% | $8.71K | −3,802 | 0.00% |
| Tower Research Capital LLC (TRC) | 2,434 | 0.11% | $4.31K | +1,374 | 0.00% |
| Barclays PLC | 83 | 0.00% | $147 | New | 0.00% |
| BlackRock, Inc. | 7 | 0.00% | $12 | – | 0.00% |
| Danske Bank A/S | 2 | 0.00% | $4 | – | 0.00% |
| Caitong International Asset Management Co., Ltd | 2 | 0.00% | $4 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 11 | 0M | 4.3% | 6 / 1 | 2 / 1 | 0M | 0M |
| Q1 2026 | 6 | 0M | 1.3% | 5 / 0 | 0 / 0 | 0M | 0M |
| Q4 2025 | 1 | 0M | 0.0% | 1 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of GRI | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 21,368 | 0.98% | $37.82K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 13,707 | 0.63% | $28.92K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 872 | 0.04% | $1.84K | 0.00% | May 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | -1 | -0.00% | -$2 | -0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Walter Marc Hertz | Chief Executive Officer, Director | 385,510 | 17.63% | Sep 22, 2025 |
| Leanne Kelly | Chief Financial Officer | 6,250 | 0.29% | Sep 22, 2025 |
| Vipin Chaturvedi | Chief Scientific Officer | 172,189 | 7.88% | Sep 22, 2025 |
| Roelof Rongen | Director | – | – | Nov 13, 2026 |
| David Charles Baker | Director | 7,843 | 0.36% | Nov 13, 2026 |
| David Leslie Szekeres | Director | – | – | Nov 13, 2026 |
| Camilla V. Simpson | Director | – | – | Nov 13, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Vipin Chaturvedi Chief Scientific Officer | Apr 21, 2023 | Award | +172,189 | – | – | 172,189 |
| Albert Agro Chief Medical Officer | Apr 21, 2023 | Award | +172,189 | – | – | 172,189 |
| Walter Marc Hertz Chief Executive Officer, Director, 10% owner | Apr 21, 2023 | Award | +385,510 | – | – | 385,510 |
| Marella Thorell Director | Dec 13, 2022 | Other | −28,517 | – | – | 9,506 |
| Marella Thorell Director | Jul 1, 2022 | Award | +38,023 | – | – | 38,023 |
| Leanne Kelly Chief Financial Officer | Jun 4, 2021 | Buy | +1,508 | $4.08 | $6.15K | 6,250 |
| Leanne Kelly Chief Financial Officer | Jun 3, 2021 | Buy | +1,085 | $4.05 | $4.39K | 4,742 |
| Leanne Kelly Chief Financial Officer | Jun 2, 2021 | Buy | +3,657 | $4.00 | $14.63K | 3,657 |
| Joseph E. Payne Director | May 26, 2021 | Buy | +6,800 | $4.50 | $30.60K | 17,500 |
| Joseph E. Payne Director | May 25, 2021 | Buy | +10,700 | $3.85 | $41.20K | 10,700 |
| Richard Ammer Director | Feb 12, 2021 | Other | +47,063 | $6.40 | $301.20K | 47,063 |
| David Charles Baker Chief Executive Officer, Director | Feb 12, 2021 | Other | +7,843 | $6.40 | $50.20K | 7,843 |
| David Charles Baker Chief Executive Officer, Director | Feb 12, 2021 | Buy | +1,000 | $8.00 | $8.00K | 8,843 |
| Pharma GmbH SALMON 10% owner | Feb 12, 2021 | Other | +47,063 | $6.40 | $301.20K | 47,063 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of GRI Bio's stock actually held short. Settlement fails (shares not delivered on time) peaked at 26,534 shares on Sep 8, 2026 over the last 90 days.
See a number that looks wrong?